Omalizumab for Severe Allergic Asthma

Patient Selection Criteria

• The National Asthma Education and Prevention Program (NAEPP) guidelines recommend omalizumab for patients aged 12 years and older with severe persistent allergic asthma whose symptoms remain inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists 1, 2
• Omalizumab is specifically indicated for patients with moderate-to-severe persistent allergic asthma, documented atopy, and inadequate control on high-dose inhaled corticosteroids or high-dose ICS plus LABA therapy 1, 2, 3

Critical Safety Requirements

• Omalizumab must be administered in a healthcare setting by providers trained to recognize and treat anaphylaxis, with an observed risk of anaphylaxis in approximately 0.09% of patients 1, 4, 5
• The FDA has issued a black-box warning for anaphylaxis risk, and patients should be observed for an appropriate period after each injection and prescribed an epinephrine autoinjector 4, 5

Mechanism of Action

• Omalizumab is a recombinant humanized monoclonal antibody that binds to the Fc portion of IgE, preventing IgE binding to high-affinity receptors (FcεRI) on mast cells and basophils, and decreasing mediator release in response to allergen exposure 2, 3

Common Pitfalls to Avoid

• The American Academy of Allergy, Asthma, and Immunology and the National Asthma Education and Prevention Program (NAEPP) guidelines recommend not using omalizumab as monotherapy or before optimizing ICS/LABA therapy, and not using in non-allergic asthma or in children <12 years 1, 2